IN2012DN01911A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN01911A IN2012DN01911A IN1911DEN2012A IN2012DN01911A IN 2012DN01911 A IN2012DN01911 A IN 2012DN01911A IN 1911DEN2012 A IN1911DEN2012 A IN 1911DEN2012A IN 2012DN01911 A IN2012DN01911 A IN 2012DN01911A
- Authority
- IN
- India
- Prior art keywords
- coq10
- sarcoma
- methods
- coenzyme
- prognosing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/54—Determining the risk of relapse
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Abstract
Methods and formulations for treating a sarcoma in humans using an epimetabolic shifter, such as Coenzyme Q10, a building block of CoQ10, a derivative of CoQ10, an analog of CoQ10, a metabolite of CoQ10, or an intermediate of the coenzyme biosynthesis pathway, are described. Methods for assessing the efficacy of treatment of, diagnosing, and prognosing sarcoma are also provided.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23684509P | 2009-08-25 | 2009-08-25 | |
PCT/US2010/046711 WO2011031503A2 (en) | 2009-08-25 | 2010-08-25 | Methods for treatment of a sarcoma using an epimetabolic shifter (coenzyme q10) |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2012DN01911A true IN2012DN01911A (en) | 2015-07-24 |
Family
ID=43730801
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN1911DEN2012 IN2012DN01911A (en) | 2009-08-25 | 2010-08-25 |
Country Status (15)
Country | Link |
---|---|
US (2) | US20110064747A1 (en) |
EP (1) | EP2470169A4 (en) |
JP (2) | JP6159085B2 (en) |
KR (1) | KR101572463B1 (en) |
CN (2) | CN102548549A (en) |
AU (2) | AU2010292532A1 (en) |
BR (1) | BR112012004237A8 (en) |
CA (1) | CA2772068C (en) |
CR (1) | CR20120120A (en) |
EA (1) | EA201270325A1 (en) |
IL (1) | IL218306B (en) |
IN (1) | IN2012DN01911A (en) |
MX (1) | MX2012002208A (en) |
SG (2) | SG10201405069QA (en) |
WO (1) | WO2011031503A2 (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20120034649A (en) * | 2009-05-11 | 2012-04-12 | 버그 바이오시스템즈, 엘엘씨 | Methods for treatment of disease using an epimetabolic shifter (coenzyme q10) |
ES2762451T3 (en) | 2011-04-04 | 2020-05-25 | Berg Llc | Treatment of tumors of the central nervous system with coenzyme Q10 |
JP6194003B2 (en) | 2012-10-09 | 2017-09-06 | ザ プロクター アンド ギャンブル カンパニー | Method for identifying or evaluating beneficial agent and composition containing the same |
JP6189962B2 (en) | 2012-10-09 | 2017-08-30 | ザ プロクター アンド ギャンブル カンパニー | How to identify synergistic cosmetic ingredient combinations |
US9138393B2 (en) | 2013-02-08 | 2015-09-22 | The Procter & Gamble Company | Cosmetic compositions containing substituted azole and methods for improving the appearance of aging skin |
US9144538B2 (en) | 2013-02-08 | 2015-09-29 | The Procter & Gamble Company | Cosmetic compositions containing substituted azole and methods for alleviating the signs of photoaged skin |
EA032775B1 (en) | 2013-04-08 | 2019-07-31 | Берг Ллк | Methofs of treating cancer using coenzyme q10 combination therapies |
JP6595478B2 (en) | 2013-09-04 | 2019-10-23 | バーグ エルエルシー | Cancer treatment by continuous injection of coenzyme Q10 |
CA2952615A1 (en) | 2014-06-17 | 2015-12-23 | Stealth Biotherapeutics Corp | Methods of identifying and monitoring mitochondrial dysfunction using monocyte screening |
CN107001451A (en) * | 2014-07-07 | 2017-08-01 | 阿勒根公司 | The SNAP25 cracked in detection tissue sample method |
CN105044360A (en) * | 2015-07-22 | 2015-11-11 | 浙江大学医学院附属邵逸夫医院 | Application of RBP4 as colorectal cancer blood serum marker and diagnostic kit |
CN106053813A (en) * | 2016-06-25 | 2016-10-26 | 林森 | Immunohistochemical kit for detecting PDK1 expression quantity of nasopharyngeal carcinoma, and application of immunohistochemical kit |
CN106947010B (en) * | 2017-04-06 | 2018-12-11 | 哈尔滨工业大学 | A method of polymerizeing induction self assembly in situ using light-initiated RAFT and prepares protein base nanoparticle |
AU2018269377A1 (en) * | 2017-05-17 | 2019-12-19 | Berg Llc | Use of coenzyme Q10 formulations in the treatment and prevention of epidermolysis bullosa |
CN107226862A (en) * | 2017-05-27 | 2017-10-03 | 南京川博生物技术有限公司 | The preparation method of specific human EWS FLI1 fusion protein antibody and preparing Ewing sarcoma diagnose antibody reagent application |
JP2022523564A (en) | 2019-03-04 | 2022-04-25 | アイオーカレンツ, インコーポレイテッド | Data compression and communication using machine learning |
IL305697A (en) * | 2021-03-05 | 2023-11-01 | Univ Central Florida Res Found Inc | Chaperonin-containing tcp-1 inhibitors for the treatment of cancer |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000040749A2 (en) * | 1999-01-06 | 2000-07-13 | Genenews Inc. | Method for the detection of gene transcripts in blood and uses thereof |
AU2003227639A1 (en) * | 2002-04-17 | 2003-10-27 | Novartis Ag | Methods to predict patient responsiveness to tyrosine kinase inhibitors |
JP2006345701A (en) * | 2003-07-01 | 2006-12-28 | Taisho Pharmaceut Co Ltd | Method for judging responsiveness to taxans |
US20060035981A1 (en) * | 2003-08-02 | 2006-02-16 | Mazzio Elizabeth A | Inhibition of anaerobic glucose metabolism and corresponding composition as a natural non-toxic approach to cancer treatment |
KR101535395B1 (en) * | 2004-01-22 | 2015-07-08 | 유니버시티 오브 마이애미 | Topical co-enzyme q10 formulations and methodns of use |
RU2006144122A (en) * | 2004-05-14 | 2008-06-20 | Лудуиг Инститьют Фор Кэнсе Рисеч (Us) | IDENTIFICATION AND CHARACTERIZATION OF SUBPOPULATION OF GLIOBLAST SUSCEPTIBLE TO IMATINIB TREATMENT |
EP1894012A2 (en) * | 2005-05-18 | 2008-03-05 | Novartis AG | Methods for diagnosis and treatment of proliferative disorders mediated by cd40 signaling |
US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
US7910316B2 (en) * | 2005-09-02 | 2011-03-22 | Toray Industries, Inc. | Kit and method for detecting urothelial cancer |
EP1777523A1 (en) * | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
EP1991701A4 (en) * | 2006-02-14 | 2010-03-17 | Dana Farber Cancer Inst Inc | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer |
US8030013B2 (en) * | 2006-04-14 | 2011-10-04 | Mount Sinai School Of Medicine | Methods and compositions for the diagnosis for early hepatocellular carcinoma |
EP2207038A4 (en) * | 2007-10-18 | 2010-10-20 | Medical Proteoscope Co Ltd | Method for prediction of postoperative prognosis, and diagnosis kit |
-
2010
- 2010-08-25 WO PCT/US2010/046711 patent/WO2011031503A2/en active Application Filing
- 2010-08-25 CN CN2010800427577A patent/CN102548549A/en active Pending
- 2010-08-25 JP JP2012526951A patent/JP6159085B2/en not_active Expired - Fee Related
- 2010-08-25 CA CA2772068A patent/CA2772068C/en not_active Expired - Fee Related
- 2010-08-25 MX MX2012002208A patent/MX2012002208A/en unknown
- 2010-08-25 BR BR112012004237A patent/BR112012004237A8/en not_active IP Right Cessation
- 2010-08-25 SG SG10201405069QA patent/SG10201405069QA/en unknown
- 2010-08-25 EA EA201270325A patent/EA201270325A1/en unknown
- 2010-08-25 KR KR1020127007679A patent/KR101572463B1/en active IP Right Grant
- 2010-08-25 IN IN1911DEN2012 patent/IN2012DN01911A/en unknown
- 2010-08-25 SG SG2012012704A patent/SG178547A1/en unknown
- 2010-08-25 CN CN201711449284.2A patent/CN108245497A/en active Pending
- 2010-08-25 US US12/868,678 patent/US20110064747A1/en not_active Abandoned
- 2010-08-25 EP EP10815861A patent/EP2470169A4/en not_active Withdrawn
- 2010-08-25 AU AU2010292532A patent/AU2010292532A1/en not_active Abandoned
-
2012
- 2012-02-23 IL IL218306A patent/IL218306B/en not_active IP Right Cessation
- 2012-03-13 CR CR20120120A patent/CR20120120A/en unknown
-
2013
- 2013-01-24 US US13/749,337 patent/US20130266557A1/en not_active Abandoned
-
2015
- 2015-12-28 JP JP2015255646A patent/JP2016136938A/en not_active Ceased
-
2016
- 2016-12-23 AU AU2016277749A patent/AU2016277749A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
SG10201405069QA (en) | 2014-10-30 |
BR112012004237A8 (en) | 2016-10-04 |
WO2011031503A2 (en) | 2011-03-17 |
EP2470169A4 (en) | 2013-03-13 |
AU2010292532A1 (en) | 2012-04-05 |
EA201270325A1 (en) | 2012-11-30 |
WO2011031503A3 (en) | 2011-07-21 |
CR20120120A (en) | 2012-07-04 |
CA2772068C (en) | 2017-03-21 |
SG178547A1 (en) | 2012-03-29 |
IL218306B (en) | 2018-05-31 |
MX2012002208A (en) | 2012-06-12 |
JP2016136938A (en) | 2016-08-04 |
KR101572463B1 (en) | 2015-11-27 |
IL218306A0 (en) | 2012-04-30 |
US20130266557A1 (en) | 2013-10-10 |
JP2013503175A (en) | 2013-01-31 |
BR112012004237A2 (en) | 2016-04-05 |
CN108245497A (en) | 2018-07-06 |
AU2016277749A1 (en) | 2017-02-02 |
EP2470169A2 (en) | 2012-07-04 |
CN102548549A (en) | 2012-07-04 |
JP6159085B2 (en) | 2017-07-05 |
CA2772068A1 (en) | 2011-03-17 |
US20110064747A1 (en) | 2011-03-17 |
KR20120050495A (en) | 2012-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2012DN01911A (en) | ||
PH12017500930A1 (en) | Hsp90 inhibitor combinations | |
MX349796B (en) | Methods for treatment of disease using an epimetabolic shifter (coenzyme q10). | |
AU2016204346A1 (en) | Methods and compositions for cell-proliferation-related disorders | |
MX2012012827A (en) | Microorganisms and methods for the biosynthesis of butadiene. | |
MX2009009292A (en) | Ppar active compounds. | |
MY172372A (en) | Compositions and methods for lowering triglycerides | |
MY162964A (en) | Microorganisms and methods for the biosynthesis of butadiene | |
TW201129938A (en) | Personal mapping system | |
MX2009009761A (en) | Compositions and kits for treating influenza. | |
MX2009006536A (en) | Organic compounds and their uses. | |
MX2012008738A (en) | Microorganisms and methods for the biosynthesis of p-toluate and terephthalate. | |
TN2010000096A1 (en) | Oxadiazole - and oxazole - substituted benzimidazole - and indole - derivatives as dgat1 inhibitors | |
SG196784A1 (en) | Stem cell cultures | |
EP2281058A4 (en) | Methods, compositions, uses, and kits useful for vitamin d deficiency and related disorders | |
EP2563926A4 (en) | Microorganisms and methods for the biosynthesis of propylene | |
ZA201100133B (en) | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives | |
WO2011005289A3 (en) | Methods and kits for measuring enzyme activity | |
WO2011083483A3 (en) | Method for treatment of inflammatory disease and disorder | |
IN2012DN01379A (en) | ||
WO2012031118A3 (en) | Cell permeable inhibitors of anaphase promoting complex | |
TN2009000495A1 (en) | Macrocycles and their uses | |
PH12014500538A1 (en) | Methods and compositions for treating leukemia | |
CO6430502A2 (en) | METHOD FOR THE TREATMENT OF A SARCOMA USING AN EPIMETABOLIC CHANGER (COENZIMA Q10) | |
MY160589A (en) | Microorganisms and methods for the biosynthesis of butadiene |